Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong

ROS1+ patients represent a unique molecular subset of non-small cell lung cancer (NSCLC). Early phase clinical trials have shown a high response rate to crizotinib in these patients. We describe a case of an 18 years old woman, never smoker, with NSCLC ROS1+ and miliary brain metastases treated with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Dis
Main Authors: Occhipinti, Mario, Falcone, Rosa, Onesti, Concetta Elisa, Botticelli, Andrea, Mazzuca, Federica, Marchetti, Paolo, Lauro, Salvatore
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2017
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5720992/
https://ncbi.nlm.nih.gov/pubmed/29268554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2017.09.74
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados